First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)
Maja J.A. de Jonge(Erasmus MC Cancer Institute), Víctor Moreno, Emiliano Calvo(South Texas Accelerated Research Therapeutics), Adam M. Petrich(AbbVie (United States)), Benedito A. Carneiro(Brown University), Toshihiko Doi(National Cancer Center Hospital East), Silpa Nuthalapati(AbbVie (United States)), Lot A. Devriese(Utrecht University), Monica Motwani(AbbVie (United States)), Sudhir Penugonda(ClearMotion (United States)), Yu‐Wei Chang(National Defense Medical Center), Dimple Modi(AbbVie (United States))
Cited by 11
Related Papers
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828